Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 21;12(3):1163–1185. doi: 10.1016/j.apsb.2021.08.020

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Natural products combine with anti-PD-1 and anti-PD-L1 antibodies to enhance the therapeutic outcomes of these antibodies. (A) Andrographolide improve the efficiency of anti-PD-1 antibodies (CD279, BP0146) by reducing PGE2 secretion; (B)Diosgenin enhance the therapeutic outcomes of anti-PD-1 antibodies (Clone 29F.1A12) by modulating intestinal microbiota; (C) Crytotanshinone improve the efficiency of anti-PD-L1 antibodies (Clone 10F.9G2) through activation of NF-κB pathway; (D) Puerarin improve the efficiency of anti-PD-L1 antibodies through inhibiting the CAFs activities.